XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue from Contracts with Customers (Tables)
9 Months Ended
Sep. 30, 2023
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2022

$

156,937

$

73,554

$

22,058

Provision related to current period sales

325,725

31,904

112,550

Changes in estimate related to prior period sales

2

3,722

589

Credits/payments made

(315,170)

(31,662)

(113,263)

Balance as of September 30, 2023

$

167,494

$

77,518

$

21,934

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2021

$

142,379

$

54,617

$

13,226

Acquired from BDSI

38,074

18,187

7,575

Provision related to current period sales

368,880

26,508

94,859

Changes in estimate related to prior period sales

(304)

(838)

(580)

Credits/payments made

(385,298)

(20,987)

(93,946)

Balance as of September 30, 2022

$

163,731

$

77,487

$

21,134

(1)Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s consolidated balance sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s consolidated balance sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s consolidated balance sheets.
Schedule of disaggregation of revenue

Three Months Ended September 30,

Nine Months Ended September 30,

2023

2022

2023

2022

Belbuca

$

45,447

$

38,802

$

132,795

$

84,413

Xtampza ER

39,800

    

38,859

128,914

103,567

Nucynta IR

24,906

27,274

80,963

83,163

Nucynta ER

22,634

17,133

62,941

53,473

Symproic

3,922

3,580

11,409

7,740

Other

1,365

1,957

Total product revenues, net

$

136,709

$

127,013

$

417,022

$

334,313